This implies caution and careful assessment of miRNome remodeling should a truncated Dicer variant be considered a therapeutic agent, such as the proposed gene therapy for Dicer deficiency in macular degeneration based on an N-terminally truncated Dicer variant termed OptiDicer (Wright et al., 2020). The gene discussed is DICER1; the disease is hyperinsulinemic hypoglycemia, familial, 4.